Sotorasib is a targeted therapy drug designed to inhibit the activity of a mutated form of the KRAS protein, specifically KRAS G12C. This mutation is commonly found in various types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, and others. Sotorasib was developed by Amgen and received FDA approval in 2021 for the treatment of KRAS G12C-mutated locally advanced or metastatic NSCLC.
